ANAPTYSBIO INC

Rule 10b5-1 Trading Arrangements

On March 14, 2024, Hollings C. Renton, a director of the Company, entered into a written plan for the sale of an aggregate 56,121 shares of common stock. The plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is scheduled to terminate no later than August 15, 2025.

On March 22, 2024, Dennis M. Fenton, a director of the Company, entered into a written plan for the sale of an aggregate 4,965 shares of common stock. The plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is scheduled to terminate no later than June 24, 2025.

The plans included a representation from the officer to the broker administering the plan that the officer was not in possession of any material nonpublic information regarding the Company or the securities subject to the plan. A similar representation was made to us in connection with the adoption of the plans under our Insider Trading Policy. Those representations were made as of the date of adoption of the plans and speak only as of that date. In making those representations, there is no assurance with respect to any material nonpublic information of which the directors were unaware, or with respect to any material nonpublic information acquired by the directors or the Company after the date of the representation.

Other than as disclosed above, during the three months ended March 31, 2024, none of the Company’s directors or officers adopted orterminated any “Rule 10b5-1 trading arrangements” or any “non-Rule 10b5-1 trading arrangements,” as each term is defined in Item 408 of Regulation S-K.